Half-year report · HY
4483.TEDINET S100X27L
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥23.1bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥41.7bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥18.5bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥4.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.4bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥152.7bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥143.0bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥136.1bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥72.8bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥64.5bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥79.9bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥78.5bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥72.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.7bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥79.5bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥78.0bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥72.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥35.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥32.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥27.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥6.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥14.7bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥10.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥1.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥36.35 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥111.34 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥33.51 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥36 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥110.23 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥33.18 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.1% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 52.9% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥428m |
| Healthcare Big Datareportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥19.9bn |
| Healthcare Big Datareportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥19.9bn |
| Healthcare Big Datareportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.8bn |
| Tele Medicinereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Tele Medicinereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Tele Medicinereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥23.1bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥23.1bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥6.0bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥401m |
| Healthcare Big Datareportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| Healthcare Big Datareportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| Healthcare Big Datareportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Tele Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Tele Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Tele Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥18.6bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥18.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 759
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)PwC Japan有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)善 塲 秀 明 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)木 村 圭 佑 | |
| Number of submission | FilingDateInstant | 1 | |
| Revenue IFRS (5-year summary) | Prior1InterimDuration | 18548000000 | JPY |
| Revenue IFRS (5-year summary) | InterimDuration | 23080000000 | JPY |
| Revenue IFRS (5-year summary) | Prior1YearDuration | 41722000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1InterimDuration | 3071000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | InterimDuration | 3657000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YearDuration | 8510000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1InterimDuration | 2189000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | InterimDuration | 2376000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 7275000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1InterimDuration | 2484000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | InterimDuration | 2452000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 8383000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1InterimInstant | 72075000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | InterimInstant | 79479000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1YearInstant | 78022000000 | JPY |
| Total assets IFRS (5-year summary) | Prior1InterimInstant | 136148000000 | JPY |
| Total assets IFRS (5-year summary) | InterimInstant | 152674000000 | JPY |
| Total assets IFRS (5-year summary) | Prior1YearInstant | 143020000000 | JPY |
| Basic earnings loss per share IFRS (5-year summary) | Prior1InterimDuration | 33.51 | |
| Basic earnings loss per share IFRS (5-year summary) | InterimDuration | 36.35 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 111.34 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1InterimDuration | 33.18 | |
| Diluted earnings loss per share IFRS (5-year summary) | InterimDuration | 36.00 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 110.23 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1InterimInstant | 0.529 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | InterimInstant | 0.521 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1YearInstant | 0.546 | |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1InterimDuration | 10777000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | InterimDuration | 6853000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YearDuration | 14685000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1InterimDuration | -4524000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | InterimDuration | -5006000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YearDuration | -3467000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1InterimDuration | 6729000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | InterimDuration | 1840000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YearDuration | 6484000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1InterimInstant | 27456000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | InterimInstant | 35863000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 32176000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 65407008 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 65416608 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 65407008 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 65416608 | |
| Number of shares held | InterimInstant_No1MajorShareholdersMember | 35459000 | |
| Shareholding ratio | InterimInstant_No1MajorShareholdersMember | 0.5421 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |